Holen Sie sich die Stockscreener-App
56.54
0.82%
-1.01
Schlusskurs vom Vortag:
$57.55
Offen:
$57.91
24-Stunden-Volumen:
11,024
Relative Volume:
0.18
Marktkapitalisierung:
$154.18M
Einnahmen:
$697.00K
Nettoeinkommen (Verlust:
$-38.97M
KGV:
-1.9446
EPS:
-29.075
Netto-Cashflow:
$-33.33M
1W Leistung:
+0.90%
1M Leistung:
-15.81%
6M Leistung:
-46.33%
1J Leistung:
-90.34%
1-Tages-Spanne:
$56.70
$58.49
1-Wochen-Bereich:
$53.81
$59.20
52-Wochen-Spanne:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
57.06 | 155.52M | 697.00K | -38.97M | -33.33M | -29.07 |
VRTX
Vertex Pharmaceuticals Inc
|
454.16 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
718.46 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.80 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
303.26 | 32.84B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Citizens lowers Spruce Biosciences stock price target on model update - Investing.com
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - BioSpace
Spruce Biosciences (NASDAQ: SPRB) posts Q1 loss and bolsters cash - Stock Titan
Spruce Biosciences (SPRB) Progresses Towards Key Regulatory Mile - GuruFocus
Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11) - TipRanks
Spruce Biosciences, Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Spruce Biosciences Reports Q1 2026 Financials, Advances TA-ERT Toward FDA Approval for MPS IIIB, and Strengthens Leadership Team - Minichart
Spruce Biosciences 1Q Research and Development Expenses $7.6M >SPRB - Moomoo
Spruce Biosciences reports Q1 2026 loss of $12.3M, cash $54.1M and $107.3M preliminary April balance - TradingView
Spruce Biosciences (SPRB) boosts cash with $69M raise, funds TA‑ERT into 2027 - Stock Titan
TradingKey - TradingKey
Ikarian Capital, Neil Shahrestani file ownership of 121,356 SPRB shares (4.8%) - Stock Titan
SPRB Stock Price, Quote & Chart | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spruce Biosciences appoints two commercial executives By Investing.com - Investing.com Australia
Spruce Biosciences Expands Leadership Team - Contract Pharma
Spruce Biosciences Adds Two Senior Commercial Executives as It Prepares Rare Disease Launch Strategy - citybiz
Spruce Biosciences appoints two commercial executives - Investing.com
Spruce Biosciences further strengthens its commercial leadership team with the appointments of Brian Walls as vice president, market access and Darren Johnson as vice president, commercial operations - marketscreener.com
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations - ChartMill
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - MSN
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
ExodusPoint entities file Schedule 13G on SPRB (SPRB) - Stock Titan
Spruce Biosciences (SPRB) Projected to Post Earnings on Tuesday - MarketBeat
SPRB Initiated Coverage by Craig-Hallum -- Rating Set to Buy - GuruFocus
Craig-Hallum initiates Spruce Biosciences stock with buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Spruce Biosciences stock with buy rating - Investing.com
Craig Hallum Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB) - MarketBeat
Craig-Hallum Initiates Spruce Biosciences(SPRB.US) With Buy Rating, Announces Target Price $140 - Moomoo
Spruce Biosciences announces proposed public offering of common stock, pre-funded warrants - MSN
Spruce Biosciences to enact 1-for-75 reverse stock split - MSN
Spruce Biosciences Prices Equity Offering to Raise Capital - The Globe and Mail
SPRB (Spruce Biosciences Inc.) posts wider than expected Q4 2025 EPS loss yet shares edge higher.Share Dilution - Cổng thông tin điện tử Tỉnh Sơn La
SPRB Spruce Biosciences reports wider than expected Q4 2025 loss, shares drop 2.32% amid investor concern. - Cổng thông tin điện tử tỉnh Lào Cai
SPRB Spruce Biosciences Inc. gains 3.53 percent even as Q4 2025 earnings miss analyst consensus estimates.Recovery Report - Cổng thông tin điện tử tỉnh Lào Cai
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionAxe Compute (NASDAQ:AGPU), Alpha Compute - Benzinga
Spruce Biosciences Enters Underwriting For $69 Million Equity Offering; Option Fully Exercised - TradingView
Spruce Biosciences prices $60M public offering at $50.00 per share - MSN
Spruce Biosciences (NASDAQ: SPRB) raises about $69.0 million in equity sale - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) sells 1.15M shares, issues pre-funded warrants - Stock Titan
Why is Spruce Biosciences stock sinking Tuesday? - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Spruce Biosciences (SPRB) and AXT (AXTI) Stocks Decline Followin - GuruFocus
SPRB: New Offering Managed by Leading Investment Firms - GuruFocus
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Is Spruce Biosciences Stock Sinking Tuesday? - Benzinga
Morning Market Movers: LOCL, CLIK, SPRC, SPRB See Big Swings - RTTNews
Spruce Biosciences prices $60M public offering at $50 per share By Investing.com - Investing.com South Africa
Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus - Benzinga
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spruce Biosciences Inc-Aktie (SPRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 15 '25 |
Option Exercise |
0.00 |
1,009 |
0 |
8,447 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
0.75%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):